Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation
Article 2017 en
Authors
MP
Miney Paquette
LF
Lionel Riou França
CT
Christine Teutsch
Abstract
1 min read
Probability of treatment persistence with dabigatran after 2 years was approximately 70%. Nearly one-half of the patients who stopped dabigatran switched to another oral anticoagulant agent. Patients from North America, and those with paroxysmal, persistent, or symptomatic AF, may be at a higher risk for discontinuing dabigatran.
Miney Paquette, Lionel Riou França, Christine Teutsch, Hans‐Christoph Diener, Shihai Lu, Sérgio Dubner, Chang Sheng, Kenneth J. Rothman, Kristina Zint, Jonathan L. Halperin, Brian Olshansky, Menno V. Huisman, Professor Gregory Lip, Robby Nieuwlaat
Christine Teutsch, Menno V. Huisman, Professor Gregory Lip, Hans‐Christoph Diener, Sérgio Dubner, Changsheng Ma, Kenneth J. Rothman, Kristina Zint, Amelie Elsaesser, Miney Paquette, Dorothee B. Bartels, Jonathan L. Halperin
Sérgio Dubner, José Francisco Kerr Saraiva, Juan Carlos Núñez Fragoso, Gonzalo Barón‐Esquivias, Christine Teutsch, Venkatesh Kumar Gurusamy, Sabrina Marler, Menno V. Huisman, Professor Gregory Lip, Cecilia Zeballos
Discussion(0)
No comments yet. Be the first to comment.